[1]
Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, Huhn D, Schmidt-Westhausen A, Reichart PA, Gross U, Stein H. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997 Feb 15:89(4):1413-20
[PubMed PMID: 9028965]
[2]
Bailly J, Jenkins N, Chetty D, Mohamed Z, Verburgh ER, Opie JJ. Plasmablastic lymphoma: An update. International journal of laboratory hematology. 2022 Sep:44 Suppl 1(Suppl 1):54-63. doi: 10.1111/ijlh.13863. Epub
[PubMed PMID: 36074710]
[3]
Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 9:125(15):2323-30. doi: 10.1182/blood-2014-10-567479. Epub 2015 Jan 30
[PubMed PMID: 25636338]
[4]
Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leukemia & lymphoma. 2010 Nov:51(11):2047-53. doi: 10.3109/10428194.2010.516040. Epub 2010 Oct 4
[PubMed PMID: 20919850]
[5]
Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leukemia research. 2011 Dec:35(12):1571-7. doi: 10.1016/j.leukres.2011.06.023. Epub 2011 Jul 12
[PubMed PMID: 21752466]
[6]
Cioc AM, Allen C, Kalmar JR, Suster S, Baiocchi R, Nuovo GJ. Oral plasmablastic lymphomas in AIDS patients are associated with human herpesvirus 8. The American journal of surgical pathology. 2004 Jan:28(1):41-6
[PubMed PMID: 14707862]
[7]
Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia. 2005 May:19(5):851-5
[PubMed PMID: 15744337]
[8]
Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Human pathology. 2002 Apr:33(4):392-404
[PubMed PMID: 12055673]
[9]
Pather S, MacKinnon D, Padayachee RS. Plasmablastic lymphoma in pediatric patients: clinicopathologic study of three cases. Annals of diagnostic pathology. 2013 Feb:17(1):80-4. doi: 10.1016/j.anndiagpath.2012.08.005. Epub 2012 Oct 2
[PubMed PMID: 23036261]
Level 3 (low-level) evidence
[10]
Kriel M, Davidson A, Pillay K, Hendricks M, Phillips LA. Clinicopathologic Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa. Journal of pediatric hematology/oncology. 2020 May:42(4):e219-e227. doi: 10.1097/MPH.0000000000001709. Epub
[PubMed PMID: 32332383]
[11]
Grimm KE, O'Malley DP. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Annals of diagnostic pathology. 2019 Feb:38():6-10. doi: 10.1016/j.anndiagpath.2018.09.014. Epub 2018 Oct 2
[PubMed PMID: 30380402]
[12]
Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. The EMBO journal. 1998 Mar 16:17(6):1700-9
[PubMed PMID: 9501091]
[13]
Bultema R, Longnecker R, Swanson-Mungerson M. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene. 2009 Mar 19:28(11):1471-6. doi: 10.1038/onc.2008.492. Epub 2009 Feb 2
[PubMed PMID: 19182823]
[14]
Miao L, Guo N, Feng Y, Rao H, Wang F, Huang Q, Huang Y. High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma. Histopathology. 2020 Jan:76(2):201-211. doi: 10.1111/his.13959. Epub 2019 Oct 13
[PubMed PMID: 31348551]
[15]
Duval A, Raphael M, Brennetot C, Poirel H, Buhard O, Aubry A, Martin A, Krimi A, Leblond V, Gabarre J, Davi F, Charlotte F, Berger F, Gaidano G, Capello D, Canioni D, Bordessoule D, Feuillard J, Gaulard P, Delfau MH, Ferlicot S, Eclache V, Prevot S, Guettier C, Lefevre PC, Adotti F, Hamelin R. The mutator pathway is a feature of immunodeficiency-related lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 2004 Apr 6:101(14):5002-7
[PubMed PMID: 15047891]
[16]
Liu Z, Filip I, Gomez K, Engelbrecht D, Meer S, Lalloo PN, Patel P, Perner Y, Zhao J, Wang J, Pasqualucci L, Rabadan R, Willem P. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway. Blood cancer discovery. 2020 Jul:1(1):112-125. doi: 10.1158/2643-3230.BCD-20-0051. Epub
[PubMed PMID: 33225311]
[17]
Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch CJ, Vilchez RA, McGregor D, Jorgensen JL. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2005 Jun:18(6):806-15
[PubMed PMID: 15578069]
[18]
Harmon CM, Smith LB. Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis. Archives of pathology & laboratory medicine. 2016 Oct:140(10):1074-8. doi: 10.5858/arpa.2016-0232-RA. Epub
[PubMed PMID: 27684979]
[19]
. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients: Erratum. AIDS (London, England). 2020 Nov 15:34(14):2159. doi: 10.1097/01.aids.0000721216.82960.36. Epub
[PubMed PMID: 33105173]
[20]
Chen BJ, Chuang SS. Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. Advances in anatomic pathology. 2020 Mar:27(2):61-74. doi: 10.1097/PAP.0000000000000253. Epub
[PubMed PMID: 31725418]
Level 3 (low-level) evidence
[21]
Morscio J, Dierickx D, Nijs J, Verhoef G, Bittoun E, Vanoeteren X, Wlodarska I, Sagaert X, Tousseyn T. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. The American journal of surgical pathology. 2014 Jul:38(7):875-86. doi: 10.1097/PAS.0000000000000234. Epub
[PubMed PMID: 24832164]
Level 1 (high-level) evidence
[22]
Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T, Villambrosía SG, Linares E, Ranchal T, Rodriguez-Pinilla M, Batlle A, Cereceda-Company L, Revert-Arce JB, Almaraz C, Piris MA. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2017 Jan:30(1):85-94. doi: 10.1038/modpathol.2016.162. Epub 2016 Sep 30
[PubMed PMID: 27687004]
[23]
Vaughan J, Perner Y, Mayne E, Wiggill T. Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use. HIV medicine. 2021 Mar:22(3):225-230. doi: 10.1111/hiv.12965. Epub 2020 Oct 6
[PubMed PMID: 33022825]
[24]
Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Dec:20(12):1877-84. doi: 10.1016/j.bbmt.2014.06.009. Epub 2014 Jun 16
[PubMed PMID: 24946718]
[25]
Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clinical lymphoma, myeloma & leukemia. 2016 Mar:16(3):122-8. doi: 10.1016/j.clml.2015.12.008. Epub 2015 Dec 22
[PubMed PMID: 26795083]
[26]
Li YJ, Li JW, Chen KL, Li J, Zhong MZ, Liu XL, Yi PY, Zhou H. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. Blood research. 2020 Mar:55(1):49-56. doi: 10.5045/br.2020.55.1.49. Epub 2020 Mar 30
[PubMed PMID: 32269975]
Level 3 (low-level) evidence
[27]
Makady NF, Ramzy D, Ghaly R, Abdel-Malek RR, Shohdy KS. The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes. Clinical lymphoma, myeloma & leukemia. 2021 Mar:21(3):e255-e263. doi: 10.1016/j.clml.2020.11.025. Epub 2020 Dec 3
[PubMed PMID: 33419717]
[28]
Dittus C, Grover N, Ellsworth S, Tan X, Park SI. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leukemia & lymphoma. 2018 Sep:59(9):2121-2127. doi: 10.1080/10428194.2017.1416365. Epub 2018 Jan 5
[PubMed PMID: 29303024]
Level 2 (mid-level) evidence
[29]
Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. British journal of haematology. 2019 Feb:184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12
[PubMed PMID: 29527667]
[30]
Cattaneo C, Finel H, McQuaker G, Vandenberghe E, Rossi G, Dreger P. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Jun:21(6):1146-7. doi: 10.1016/j.bbmt.2015.03.008. Epub 2015 Mar 14
[PubMed PMID: 25783635]
[31]
Cattaneo C, Re A, Ungari M, Peli A, Casari S, Castelnuovo F, Fisogni S, Lonardi S, Pellegrini V, Petullà M, Facchetti F, Rossi G. Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience. Leukemia & lymphoma. 2015 Jan:56(1):267-9. doi: 10.3109/10428194.2014.911867. Epub 2014 Jun 16
[PubMed PMID: 24712980]
[32]
Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. The oncologist. 2010:15(3):293-9. doi: 10.1634/theoncologist.2009-0304. Epub 2010 Feb 18
[PubMed PMID: 20167839]
[33]
Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M, Chen W, Díez-Martín JL, Liu JJ, Miranda RN, Montoto S, Nanaji NM, Navarro JT, Seegmiller AC, Vose JM. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012 Nov 1:118(21):5270-7. doi: 10.1002/cncr.27551. Epub 2012 Apr 17
[PubMed PMID: 22510767]
[34]
PDQ Adult Treatment Editorial Board. Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. 2002:():
[PubMed PMID: 26389473]
[35]
Hui D, Hannon BL, Zimmermann C, Bruera E. Improving patient and caregiver outcomes in oncology: Team-based, timely, and targeted palliative care. CA: a cancer journal for clinicians. 2018 Sep:68(5):356-376. doi: 10.3322/caac.21490. Epub 2018 Sep 13
[PubMed PMID: 30277572]